Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Blood (2021) 138 (26): 2828–2837.

https://doi.org/10.1182/blood.2021013379

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era

Blood (2021) 137 (1): 39–48.

https://doi.org/10.1182/blood.2020005112

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

Blood (2017) 130 (20): 2196–2203.

https://doi.org/10.1182/blood-2017-06-788877

Published: 2017

Journal Articles

Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Craig H. Moskowitz, Matt J. Matasar, Andrew D. Zelenetz, Stephen D. Nimer, John Gerecitano, Paul Hamlin, Steven Horwitz, Alison J. Moskowitz, Ariela Noy, Lia Palomba, Miguel-Angel Perales, Carol Portlock, David Straus, Jocelyn C. Maragulia, Heiko Schoder, Joachim Yahalom

Blood (2012) 119 (7): 1665–1670.

https://doi.org/10.1182/blood-2011-10-388058

Published: 2012

Journal Articles

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

Paul A. Hamlin, Jr, MD, Maria Alma Rodriguez, MD, Ariela Noy, MD, Carol S. Portlock, MD, David Straus, MD, Peter McLaughlin, MD, Barbara Pro, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Brett Wegner, Otilia Dumitrescu, MD, Neetha Pandit Tasker, MD, Craig H Moskowitz, MD, Andrew D Zelenetz, MD, PhD

Blood (2010) 116 (21): 1793.

https://doi.org/10.1182/blood.V116.21.1793.1793

Published: 2010

Journal Articles

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Miles Prince, MD, FRACP, FRCPA, Madeleine Duvic, MD, Ann Martin, MD, Wolfram Sterry, MD, Chalid Assaf, MD, David Straus, MD

Blood (2010) 116 (21): 4158.

https://doi.org/10.1182/blood.V116.21.4158.4158

Published: 2010

Journal Articles

Doxorubicin, Vinblastine and Gemcitabine (AVG), a Novel Regimen Excluding Bleomycin for the Treatment of Early Stage Hodgkin Lymphoma (HL): Results of CALGB 50203.

David Straus, MD, Ann LaCase, MD, Malik Juweid, MD, Lale Kostakogolu, MD, Nathan Hall, MD, Jeffery Johnson, MS, Sin-Ho Jung, Ph.D., George Canellos, MD, Lawrence Schwartz, MD, Bruce Cheson, MD

Blood (2007) 110 (11): 214.

https://doi.org/10.1182/blood.V110.11.214.214

Published: 2007

Journal Articles

Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.

Larisa Geskin, MD, FAAD, Francine Foss, MD, Madeleine Duvic, MD, David Straus, MD, Steven Horwitz, MD, Jasmine Zain, MD, Timothy Kuzel, MD, Christiane Querfeld, MD, Kim Campbell, PhD, Robert Knobler, MD

Blood (2007) 110 (11): 2561.

https://doi.org/10.1182/blood.V110.11.2561.2561

Published: 2007

Journal Articles

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

John Gerecitano, MD, PhD, Carol Portlock, MD, Ariela Noy, MD, Paul Hamlin, MD, Craig Moskowitz, MD, David Straus, MD, Steven M. Horwitz, MD, Maria Lia Palomba, MD, Otilia-Liana Dumitrescu, MD, Jennifer Pappanicholaou, Ellen Neylon, Rachel Hamelers, Andrew Zelenetz, MD,PhD, Thomas J. Myers, MD, Anthony L. Boral, MD, Owen A. O’Connor, MD,PhD

Blood (2006) 108 (11): 2759.

https://doi.org/10.1182/blood.V108.11.2759.2759

Published: 2006

Journal Articles

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

Steven Horwitz, MD, Craig Moskowitz, MD, Tarun Kewalramani, MD, Paul Hamlin, MD, David Straus, MD, Owen O’Connor, MD, PhD, Ariela Noy, MD, Carol Portlock, MD, Stephen Nimer, MD, PhD, M. Lia Palomba, MD, PhD, Andrew Zelenetz, MD, PhD

Blood (2005) 106 (11): 2679.

https://doi.org/10.1182/blood.V106.11.2679.2679

Published: 2005

Journal Articles

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Owen O’Connor, MD, PhD, John Wright, Craig Moskowitz, MD, Barbara MacGregor-Cortelli, RN, David Straus, MD, Andrew Evans, MD, Jane Winter, MD, Omer Koc, MD, Nancy Horvath, RN, Susan Blumel, MD, Julie Vose, MD, David Schenkein, MD, Andrew Zelenetz, MD

Blood (2004) 104 (11): 607.

https://doi.org/10.1182/blood.V104.11.607.607

Published: 2004

Journal Articles

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Tarun Kewalramani, Andrew D. Zelenetz, Stephen D. Nimer, Carol Portlock, David Straus, Ariela Noy, Owen O'Connor, Daniel A. Filippa, Julie Teruya-Feldstein, Alison Gencarelli, Jing Qin, Alyson Waxman, Joachim Yahalom, Craig H. Moskowitz

Blood (2004) 103 (10): 3684–3688.

https://doi.org/10.1182/blood-2003-11-3911

Published: 2004

Journal Articles

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz, Tania Trippett, Eric E. Hedrick, Daniel A. Filippa, Diane Louie, Maria Gonzales, Janine Walits, Nancy Coady-Lyons, Jing Qin, Richard Frank, Joseph R. Bertino, Andre Goy, Ariela Noy, James P. O'Brien, David Straus, Carol S. Portlock, Joachim Yahalom

Blood (2001) 97 (3): 616–623.

https://doi.org/10.1182/blood.V97.3.616

Published: 2001

NARROW

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Doxorubicin, Vinblastine and Gemcitabine (AVG), a Novel Regimen Excluding Bleomycin for the Treatment of Early Stage Hodgkin Lymphoma (HL): Results of CALGB 50203.

Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only